Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fluconazole is an antifungal agent available for the treatment of oropharyngeal and esophageal candida and cryptococcal meningitis. It has been found to be equal to or more efficacious than amphotericin B in treating oral and esophageal candidiasis and in providing maintenance therapy for cryptococcal meningitis. It still remains to be seen if it can be equally effective in treating acute cryptococcal infections and systemic candidiasis. In these fungal infections, amphotericin B remains the clinically proven drug of choice. To its advantage, it does not cause acute renal failure, bone marrow depression, or suppress corticosteroid production which are significant drawbacks to other available agents. It is a drug with great promise for its specific indications, but more studies in renal failure and organ transplant patients are needed to firmly establish its efficacy in these populations.
 ...
PMID:Medication review: fluconazole. 175 Jul 92

Patients with immune depression are at increased vulnerability to a variety of mycotic infections. These range from mucosal and disseminated candidiasis to invasive aspergillosis to regional mycoses, such as histoplasmosis and Penicillium morneffei, and the emerging mycoses including zygomycetes, phaeohyphomycetes, Fusarium sp, Trichosporon sp, and others. An increasing variety of antifungal drugs, among which are fluconazole and itraconazole, are used for the treatment of these opportunistic infections. Fluconazole has excellent absorption, linear renal excretion of largely active drug, and limited spectrum, primarily against yeast pathogens such as Candida sp. In its capsule formulation, itraconazole has broader activity, including mycelial pathogens, but suffers from irregular absorption, lack of intravenous formulation, and complex hepatic excretion. Itraconazole has recently undergone reformulation as a solution, which gives significant added advantages in bioavailability and increases the practical applications. It is at present unclear whether voriconazole, SCH56592, or itraconazole solution will be equally potent and have a similar range of applications.
 ...
PMID:Itraconazole: managing mycotic complications in immunocompromised patients. 967 33

Children suffering malignant diseases can experience phases of bone marrow depression during intensive chemotherapy. The influence of antibiotic sequence therapy on the course of diseases was examined in 41 pediatric patients with malignant diseases. Inclusion criteria were neutropenia (ANC < 500/microL), rectal body temperature over 38.5 degrees C, and increased C-reactive protein (CRP, cutoff > 5.0 mg/L). The first stage of therapy comprised the following antibiotics: piperacillin, teicoplanin, and gentamicin. In stage 2 imipenem, teicoplanin, and tobramycin were administered. Fluconazole was the antifungal drug of choice in stages 1 and 2. In the first level of antibiotic therapy 68% of the patients showed a positive reaction. The C-reactive protein was a sensitive parameter, which significantly decreased with 3 days of therapy. A total of 72% of the bacteriological smears were sterile. All patients survived the septic phase.
 ...
PMID:Antibiotic sequential therapy for febrile neutropenia in pediatric patients with malignancy. 1068 19